Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft (TAILOR)

In this study, patients will be observed who receive an E-liac Stent Graft for treatment of isolated iliac aneurysms or an E-liac Stent Graft in combination with one of the following AAA stent grafts: E-tegra Stent Graft, Endurant AAA Stent Graft, Zenith AAA Endovascular Graft, Gore Excluder AAA Endoprosthesis for treatment of aorto-iliac aneurysms.

Objectives of this post-market registry are:

Primary: To prevent the risk of rupture and death by the treatment of common iliac aneurysm with an iliac branched stent graft (E-liac, JOTEC) Secondary: Evaluation of safety and feasibility of the E-liac Stent Graft System used in endovascular treatment of uni- or bilateral aorto-iliac or iliac aneurysm.

Study Overview

• Status: Completed
• Conditions: AAA; Iliac Aneurysm
• Intervention / Treatment: Device: Endovascular aorto-iliac repair

• Study Type: Observational
• Enrollment (Actual): 71

Contacts and Locations

Study Locations

• France
  • Nantes, France
    • CHU Nantes
  • Rennes, France
    • CHU Rennes

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Male and female patients with unilateral or bilateral common iliac aneurysm, treated with the E-liac Stent Graft System

Description

Inclusion Criteria:

• Unilateral or bilateral aorto-iliac or iliac aneurysm
• Suitable for endovascular repair
• Patient must be compliant with life- long follow-up investigations
• >18 years old
• lliac/femoral access vessel morphology compatible with the implantation procedure and the 18Fr (6mm OD) delivery system
• Non-aneurysmal common iliac artery landing area in case of iliac artery aneurysm ≥ 20mm
• Diameter of the common iliac artery in the proximal landing area: 12mm to 17mm
• Non-aneurysmal external iliac artery segment distal to the aneurysm ≥15mm
• Diameter of the external iliac artery in the distal landing area: 8mm to 13mm
• Non-aneurysmal internal iliac artery segment distal to the aneurysm ≥15mm
• Angle between external iliac artery and internal iliac artery ≤50°
• Thrombus free iliac lumen in the area of iliac bifurcation to open hypogastric side branch and to implant covered stent ≥18mm
• Sufficiently open internal iliac arterv ostium
• Patients must comply with the instructions for use.
• Patients with common iliac aneurysm with a diameter ≥30mm when isolated or common iliac aneurysm with a diameter >25mm when associated with an abdominal aortic aneurysm
• Unilateral or bilateral common iliac aneurysm
• Patient's anatomy must be fit for stent graft placement on preoperative angio CT scan.
• Patient is affiliated to the social security or equivalent system.
• The patient must be available for the appropriate follow-up times for the duration of the study.
• Patient has been informed of the nature of the study, agrees to its provisions and has signed the informed consent from.

Exclusion Criteria:

• Patients who do not meet the instructions for use
• Patients with one of the contraindications as indicated in the instructions for use
• Patients with a stenotic internal iliac ostium of < 4mm in Diameter
• Patients with severe internal iliac atherosclerosis
• Patients that do not have a suitable landing area in the main stem of the IIA (maximum diameter in landing area <12mm)
• Patients with pseudoaneurysms
• Patients with symptomatic and ruptured iliac aneurysms
• Patients pretreated with a AAA stent graft or a bifurcated vascular graft
• Patient with thrombocytopenia
• Patient with an estimated glomerular filtration rate < 30 ml/min/1,73m2 immediately before the Intervention
• Female of child bearing potential
• In the lnvestigator's opinion patient has (a) eo-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements, or impact the scientific integrity of the study
• Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints
• Patient with malignancy needing chemotherapy or radiation
• Patients with life expectancy of less than 36 months
• Patient minor or under guardianship

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical success	Clinical success related to the E-liac Stent Graft combines the following criteria (adapted from Chaikof 2002): Clinical success should be reported on an intent-to-treat Basis; requires successful deployment of the E-liac Stent Graft at the intended location without; Death as a result of iliac aneurysm-related treatment; Type I or III endoleak; E-liac Stent Graft infection; E-liac Stent Graft thrombosis (including internal iliac artery thrombosis); Aneurysm growth >3mm in maximum diameter for common iliac aneurysm and >5mm in maximum diameter for aortic aneurysm at 12, 24, and 36 months follow-up; Common iliac aneurysm rupture; Conversion to open repair; Failure of E-liac Stent Graft integrity	30 days follow-up

Collaborators and Investigators

• Sponsor: JOTEC GmbH
• Investigators: Principal Investigator: Adrien Kaladji, Prof., CHU Rennes

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2016
• Primary Completion (Actual): July 5, 2024
• Study Completion (Actual): July 5, 2024

Study Registration Dates

• First Submitted: February 23, 2016
• First Submitted That Met QC Criteria: February 23, 2016
• First Posted (Estimated): February 26, 2016

Study Record Updates

• Last Update Posted (Actual): February 17, 2026
• Last Update Submitted That Met QC Criteria: February 12, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: iliac side branch
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Aneurysm; Iliac Aneurysm
• Other Study ID Numbers: TAILOR

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED